Info

Chondros, Inc. is a development stage company involved in the discovery, development, and commercialization of novel methodologies, proprietary processing techniques, and clinical applications in the dynamic field of human tissue repair. For the past five years, experimental work at Johns Hopkins University and the Orthopaedic Research laboratories of David Hungerford, MD at Good Samaritan Hospital, in Baltimore, MD has resulted in exciting advancements in techniques of rapid cell proliferation, cell scaffold design, and efficiencies in base cell harvesting. We believe that these advancements have wide ranging applications for defining the next module of progress for the field and that Chondros can enter into strategic collaborations with those companies either already active in the field of human tissue engineering, or with those that might be contemplating entry. Human tissue engineering has opened a new frontier in the development of implant materials for surgery. While the focus of Chondros, Inc. has been on cartilage applications, including orthopaedics, otolaryngology-head and neck surgery, and facial plastic reconstruction, considerable work in liver, pancreas and other regenerative organs is ongoing as well. Bioabsorbable scaffolds, seeded with harvested cells that have been grown ex-vivo can be implanted in the appropriate surgical site to effect defect repair or to create new masses of organ tissues to replace damaged areas. These implants in turn, promote continued tissue regeneration rather than serving as merely inert tissue replacement. The processes involved in harvesting, expanding, and implanting organized cell structures are complicated, and require significant skill expertise and clinical and scientific cooperation. The resources that the Chondros team has assembled represent the leading edge in these fields, and prior to the organization of the company, but in a collaborative mode, have been able to demonstrate quantifiable progress over the current commercial options. It is expected that for the next 2-3 years, the emphasis of Chondros will remain largely technical, aimed at further refinements and expansion of the company's proprietary technologies.